HOME » News & Media

    Vyome Biosciences Raises $14M Series C for Acne Drug Trials

     

    23rd August 2016. Vyome Biosciences, a clinical-stage speciality bio-pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes announced in Monday that it has closed $14 million Series-C financing round. This financing round was led by Perceptive Advisors, a leading New York based life sciences fund and, Romulus Capital, a Boston-based venture capital firm, along with participation from existing investors including Kalaari Capital, Sabre Partners and Aarin Capital.

    Visit: www.vyome.in
    Copyright © 2021 Vyome Biosciences Private Limited.

    Copyright © 2015 Vyome Therapeutics Inc. All rights reserved.